Inclusion Criteria:

• Age ≥ 18 years at the time of informed consent.
• Ability to provide written informed consent in accordance with Swiss Human Research Act (HRA) and ICH-GCP.
• Documented plasma lipoprotein(a) [Lp(a)] concentration:

High Lp(a) cohort: ≥ 125 nmol/L (approximately ≥ 75th percentile) Low Lp(a) comparator cohort (if applicable): < 25-30 nmol/L

• Clinically stable at the time of inclusion, with no acute cardiovascular event within the previous 3 months.
• Willingness and ability to comply with all study procedures, including blood sampling and study medication intake.
• For women of childbearing potential: willingness to use adequate contraception during the study period (if applicable according to local ethics requirements).

Exclusion Criteria:

• Cardiovascular and bleeding-related conditions Active bleeding or known bleeding disorder. History of hemorrhagic stroke or intracranial hemorrhage. High risk of bleeding as judged by the investigator. Platelet count < 100 × 10⁹/L at screening. Known platelet function disorder.
• Contraindications to study medications Known hypersensitivity or contraindication to aspirin (acetylsalicylic acid) or clopidogrel.

History of aspirin-induced asthma, severe NSAID intolerance, or anaphylactic reaction to salicylates.

Active peptic ulcer disease or clinically significant gastrointestinal bleeding within the past 6 months.

- Concomitant medications and interference with platelet function Current use of dual antiplatelet therapy (DAPT), oral anticoagulants (e.g., DOACs, vitamin K antagonists), or other potent antithrombotic agents that cannot be safely interrupted.

Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 7 days prior to study entry (unless discontinued per protocol).

Use of P2Y12 inhibitors or aspirin within an insufficient washout period. - Clinical conditions Severe hepatic impairment (ALT/AST > 3× ULN) or severe renal impairment (eGFR < 30 mL/min/1.73 m²).

Active malignancy requiring systemic chemotherapy. Known hematologic disorder affecting platelet function or coagulation. Acute infection or inflammatory condition likely to affect platelet function.

- Other exclusions Pregnancy or breastfeeding. Participation in another interventional clinical trial within the last 30 days or 5 half-lives of the investigational product, whichever is longer.

Any condition that, in the opinion of the investigator, would interfere with study participation, compliance, or interpretation of results.